Please use this identifier to cite or link to this item:
|Title:||Finding Synergies for the 3Rs – Repeated Dose Toxicity Testing: Report from an EPAA Partners' Forum|
|Authors:||LAROCHE CHARLES; ANNYS ERWIN; BENDER HANS; BOTELHO DANIELLE; BOTHAM PHIL; BRENDLER SCHWAAB SUSANNE; CLAYTON RICK; CORVARO MARCO; DAL NEGRO GIANNI; DELANNOIS FRÉDÉRIQUE; DENT MATTHEW; DESAINTES CHRISTIAN; DESPREZ BERTRAND; DHALLUIN STEPHANE; HARTMANN ANDREAS; HOFFMANN-DOERR SIMONE; HUBESCH BRUNO; IRIZAR AMAIA; MANOU IRENE; MULLER BORIS P.; NADZIALEK STEPHANIE; PRIETO PERAITA MARIA DEL PILAR; RASENBERG MIKE; ROGGEBAND ROB; ROWAN TIM G; SCHUTTE KATRIN; VAN DE WATER BOB; WESTMORELAND CARL; WHELAN MAURICE; WILSCHUT ANNETTE; ZVONIMIR ZVONAR; CRONIN MARK|
|Citation:||REGULATORY TOXICOLOGY AND PHARMACOLOGY vol. 108 p. 104470|
|Publisher:||ACADEMIC PRESS INC ELSEVIER SCIENCE|
|Type:||Articles in periodicals and books|
|Abstract:||The European Partnership for Alternative Approaches to Animal Testing (EPAA) convened a Partners' Forum on repeated dose toxicity (RDT) testing to identify synergies between industrial sectors and stakeholders along with opportunities to progress these in existing research frameworks. Although RTD testing is not performed across all industrial sectors, the OECD accepted tests can provide a rich source of information and play a pivotal role for safety decisions relating to the use of chemicals. Currently there are no validated alternatives to repeated dose testing and a direct one-to-one replacement is not appropriate. However, there are many projects and initiatives at the international level which aim to implement various aspects of replacement, reduction and refinement (the 3Rs) in RDT testing. Improved definition of use, through better problem formulation, aligned to harmonisation of regulations is a key area, as is the more rapid implementation of alternatives into the legislative framework. Existing test designs can be optimised to reduce animal use and increase information content. Greater use of exposure-led decisions and improvements in dose selection will be beneficial. In addition, EPAA facilitates sharing of case studies demonstrating the use of Next Generation Risk Assessment applying various New Approach Methodologies to assess RDT.|
|JRC Directorate:||Health, Consumers and Reference Materials|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.